Delcath Systems (DCTH) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Delcath Systems (DCTH) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 35.5% versus a loss of 25.0%. Over five years, DCTH leads with a +59.8% price change compared with -23.8% for SNN. Smith & Nephew SNATS is the larger company by market cap ($11.28 billion vs $521.9 million), about 21.6 times the size.
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 334.2x for Delcath Systems). Smith & Nephew SNATS pays a dividend yielding 1.47%, while Delcath Systems does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | SNN |
|---|---|---|
| Share price | $15.04 | $26.96 |
| Market cap | $521.87M | $11.28B |
| 1-day change | -2.21% | +0.26% |
| YTD return | +48.91% | -17.83% |
| 1-year return | +35.50% | -24.97% |
| 5-year return | +59.83% | -23.82% |
| P/E ratio (TTM) | — | 18.34 |
| Forward P/E | 334.22 | 11.18 |
| EPS (TTM) | $0.01 | $1.47 |
| Dividend yield | 0.00% | 1.47% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | — | $6.16B |
| Revenue growth (YoY) | — | +6.09% |
| Net income (latest FY) | — | $625.00M |
| Gross margin | — | 68.01% |
| Operating margin | — | 12.88% |
| Net margin | — | 10.14% |
| 52-week high | $17.42 | $37.51 |
| 52-week low | $8.12 | $26.12 |
| Distance from 52-week high | -13.66% | -28.13% |
| Analyst consensus | none | hold |
| Avg. price target upside | +59.57% | +19.88% |
| Average volume | 479.73K | 1.65M |
| Shares outstanding | 34.70M | 418.52M |
| Employees | 156 | 17,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Smith & Nephew SNATS is about 21.6 times larger than Delcath Systems by market value ($11.28B vs $521.87M).
- DCTH has outperformed SNN by 60.5 percentage points over the past year.
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Healthcare · Medical Devices · 156 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Healthcare · Medical Devices · 17,000 employees
DCTH vs SNN FAQ
Which is bigger, Delcath Systems or Smith & Nephew SNATS?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.28B compared with $521.87M for Delcath Systems (DCTH).
Which stock has performed better over the past year, DCTH or SNN?
DCTH returned +35.50% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Delcath Systems or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while Delcath Systems does not currently pay a regular dividend.
Are Delcath Systems and Smith & Nephew SNATS in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.